This post was originally published on this sitehttps://i-invdn-com.akamaized.net/news/LYNXNPEB8506G_M.jpg
Orbimed Advisors’s holding in Corvus Pharmaceuticals Inc increased to about 8.1 million shares with the purchase.
Orbimed Advisors first bought Corvus Pharmaceuticals Inc stock in the first quarter of 2016. Orbimed Advisors also owns Bristol-Myers Squibb Co (NYSE:BMY), Merck (MRK), Larimar Therapeutics, Inc. (LRMR) and Pfizer (NYSE:PFE). Corvus Pharmaceuticals Inc is its number thirty five position by number of shares and market value among biotechnology & life sciences stocks.
In contrast, Millennium Management reduced CRVS shares.